We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 7,278

CPSC snapshot - a fight in December and renewed focus on safety

  • Alston & Bird LLP
  • -
  • USA
  • -
  • August 20 2014

Here have been some interesting developments relating to the high powered magnets that have been the focus of so much attention by the CPSC. Although

FDA to strengthen oversight of certain in vitro diagnostic devices

  • Latham & Watkins LLP
  • -
  • USA
  • -
  • August 20 2014

On July 31, 2014, the U.S. Food and Drug Administration (FDA; Agency) announced its intent to strengthen regulation of certain in vitro diagnostics

FDA releases revised de novo pathway guidance

  • Hogan Lovells
  • -
  • USA
  • -
  • August 19 2014

On August 14, 2014, the U.S. Food and Drug Administration (FDA or the Agency) released an updated draft guidance document regarding de novo premarket

US Department of Homeland Security issues advanced notice of rulemaking for CFATS program under EO 13650 directives

  • Squire Patton Boggs
  • -
  • USA
  • -
  • August 19 2014

As previously detailed in several of our prior posts, the Presidential Executive Order (EO) 13650-Improving Chemical Facility Safety and Security

Amnesty International continues to push for en banc rehearing in conflict minerals case

  • Stinson Leonard Street LLP
  • -
  • USA
  • -
  • August 19 2014

Amnesty International has filed a supplemental brief which continues to advocate for a rehearing en banc in the conflict minerals case. The argument

FDA now enforcing "gluten-free" labeling rule

  • Reinhart Boerner Van Deuren SC
  • -
  • USA
  • -
  • August 19 2014

As of August 5, 2014, all packaged foods labeled "gluten-free" (or other equivalent terms, such as "free of gluten," "no gluten" and "without

Unsubstantiated product claims bring substantial civil penalties

  • Seyfarth Shaw LLP
  • -
  • USA
  • -
  • August 19 2014

The U.S. Environmental Protection Agency recently ordered an orthotic shoe insert manufacturer to pay over $210,000 in civil penalties for making

FDA public hearing on the implementation of Generic Drug User Fee Amendments (Sept. 17)

  • Reed Smith LLP
  • -
  • USA
  • -
  • August 19 2014

On September 17, 2014 the Food and Drug Administration ("FDA") is holding a public hearing at the College Park Marriot Hotel and Conference Center

Eighth Circuit dismisses whistleblower's suit finding facts were already publicly disclosed

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 18 2014

In an August 7, 2014 opinion, the Eighth Circuit upheld the dismissal of a whistleblower's suit alleging that a number of pain pump device makers had

POM doesn’t seem to have changed much

  • Reed Smith LLP
  • -
  • USA
  • -
  • August 18 2014

Although the Supreme Court's recent decision in POM Wonderful, which we blogged about here, didn't involve preemption, we were worried that, at least